Zacks: Brokerages Expect Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.40 Earnings Per Share

Equities analysts expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce ($0.40) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.39). Corvus Pharmaceuticals posted earnings per share of ($0.58) in the same quarter last year, which would suggest a positive year over year growth rate of 31%. The business is scheduled to announce its next earnings results on Thursday, March 7th.

On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.74). For the next year, analysts anticipate that the company will report earnings of ($1.59) per share, with EPS estimates ranging from ($1.65) to ($1.52). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, November 1st. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12.

Several equities analysts have recently commented on CRVS shares. Zacks Investment Research lowered shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Wedbush reaffirmed an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, August 8th. BidaskClub upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st. Credit Suisse Group upgraded shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $11.00 to $15.00 in a research note on Wednesday, August 15th. Finally, Cowen restated a “buy” rating on shares of Corvus Pharmaceuticals in a research note on Friday, November 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $13.58.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Corvus Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 677,974 shares of the company’s stock worth $5,817,000 after purchasing an additional 13,578 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Corvus Pharmaceuticals by 22.2% during the third quarter. Renaissance Technologies LLC now owns 396,900 shares of the company’s stock worth $3,405,000 after acquiring an additional 72,000 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the third quarter worth about $182,000. Bridgeway Capital Management Inc. lifted its holdings in Corvus Pharmaceuticals by 23.1% in the third quarter. Bridgeway Capital Management Inc. now owns 104,600 shares of the company’s stock worth $897,000 after purchasing an additional 19,600 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Corvus Pharmaceuticals by 66.6% in the third quarter. Dimensional Fund Advisors LP now owns 260,701 shares of the company’s stock worth $2,237,000 after purchasing an additional 104,230 shares during the period. 87.42% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:CRVS traded up $0.29 on Wednesday, hitting $6.27. The stock had a trading volume of 1,414 shares, compared to its average volume of 78,899. The firm has a market capitalization of $175.11 million, a price-to-earnings ratio of -2.24 and a beta of -0.65. Corvus Pharmaceuticals has a 1-year low of $5.66 and a 1-year high of $13.91.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Recommended Story: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit